The stock of Portage Biotech Inc (PRTG) has gone down by -20.70% for the week, with a -63.44% drop in the past month and a -66.79% drop in the past quarter. The volatility ratio for the week is 21.15%, and the volatility levels for the past 30 days are 16.59% for PRTG. The simple moving average for the past 20 days is -31.07% for PRTG’s stock, with a -82.49% simple moving average for the past 200 days.
Is It Worth Investing in Portage Biotech Inc (NASDAQ: PRTG) Right Now?
Moreover, the 36-month beta value for PRTG is 101.27. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRTG is 8.67M and currently, short sellers hold a 0.63% of that float. On July 03, 2024, PRTG’s average trading volume was 506.56K shares.
PRTG) stock’s latest price update
Portage Biotech Inc (NASDAQ: PRTG) has experienced a decline in its stock price by -10.66 compared to its previous closing price of 0.20. However, the company has seen a fall of -20.70% in its stock price over the last five trading days. globenewswire.com reported 2024-04-12 that WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
Analysts’ Opinion of PRTG
Many brokerage firms have already submitted their reports for PRTG stocks, with Oppenheimer repeating the rating for PRTG by listing it as a “Outperform.” The predicted price for PRTG in the upcoming period, according to Oppenheimer is $26 based on the research report published on July 18, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRTG reach a price target of $32. The rating they have provided for PRTG stocks is “Buy” according to the report published on March 07th, 2022.
Oppenheimer gave a rating of “Outperform” to PRTG, setting the target price at $30 in the report published on September 21st of the previous year.
PRTG Trading at -33.58% from the 50-Day Moving Average
After a stumble in the market that brought PRTG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.57% of loss for the given period.
Volatility was left at 16.59%, however, over the last 30 days, the volatility rate increased by 21.15%, as shares sank -40.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.39% lower at present.
During the last 5 trading sessions, PRTG fell by -20.70%, which changed the moving average for the period of 200-days by -93.86% in comparison to the 20-day moving average, which settled at $0.2481. In addition, Portage Biotech Inc saw -90.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRTG
The total capital return value is set at -0.4. Equity return is now at value -144.22, with -110.92 for asset returns.
Based on Portage Biotech Inc (PRTG), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -57.33. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1002.26.
Currently, EBITDA for the company is -16.62 million with net debt to EBITDA at 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.78.
Conclusion
To wrap up, the performance of Portage Biotech Inc (PRTG) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
